Pectin supplement for fatty liver disease
Part of Digestive system clinical trials.
This study tests whether a pectin supplement (a fiber found in fruits) can reduce inflammation and improve liver and metabolic health in people with fatty liver disease (MASLD). You might be eligible if you have MASLD, a healthy weight range, and can avoid certain medications and foods.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of MASLD (fatty liver disease) with at least 5% liver fat confirmed by a scan or biopsy.
- Your BMI should be between 18.5 and 39.9, and your weight must have been stable (within 3 kg) for the past 3 months.
- If you have diabetes, your blood sugar must be well-controlled (HbA1c below 7%).
- You cannot have allergies to soya, milk, chocolate, or pectin.
- You must not have taken antibiotics, probiotics, or prebiotics in the last 3 months, and you cannot be on a vegan diet.
- You must not have any gastrointestinal conditions like celiac, IBS, or IBD, and you must not drink more than 14 (women) or 21 (men) units of alcohol per week.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a probiotic mixture can improve liver health in people with moderate fatty liver disease (MASLD). It looks at how the probiotic affects liver fat, inflammation, and metabolism.
This study tests whether a special supplement (made from cacao, nopal, and crickets) can help improve fatty liver disease in people with excess body fat. Fatty liver disease happens when fat builds up in the liver, and this trial investigates whether these natural ingredients can reduce that buildup.
This study tests whether adding a liver stiffness measurement to a lifestyle program helps people with MASLD (a type of fatty liver disease) improve their liver health. It is designed for people who have fatty liver and at least one sign of metabolic syndrome, like high blood pressure or diabetes.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
This study tests a new blood test to help diagnose fatty liver disease and liver fibrosis. It aims to see how well the test works compared with a liver biopsy. Your participation could help improve diagnosis for others.
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.